Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Lechevalier

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|October 3, 2019
An R-Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry DataFrancis Lacombe, Nicolas Lechevalier, Jean Philippe Vial, et al.
Cancers|February 10, 2021
Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid LeukemiaJean Philippe Vial, Nicolas Lechevalier, Francis Lacombe, et al.
Annales De Biologie Clinique|October 21, 2023
Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patientsVictor-Emmanuel Brett, Marie-Sarah Dilhuydy, Nicolas Lechevalier, et al.
American Journal of Clinical Pathology|November 2, 2018
Reference Values for WBC Differential by Hematoflow AnalysisMarion Magierowicz, Nicolas Lechevalier, Nicolas Freynet, et al.
Ejhaem|February 26, 2024
Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemiaCéline Row, Nicolas Lechevalier, Jean Philippe Vial, et al.
Leukemia Research|January 12, 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry studyIbrahim Didi, Jean-Marc Alliot, Pierre-Yves Dumas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid LeukemiaAlban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Cancer Medicine|February 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapyHarmony Leroy, Noémie Gadaud, Emilie Bérard, et al.
Cancers|July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry StudyPierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Cancers|March 29, 2020
Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry StudySarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|October 3, 2019
An R-Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry DataFrancis Lacombe, Nicolas Lechevalier, Jean Philippe Vial, et al.
Cancers|February 10, 2021
Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid LeukemiaJean Philippe Vial, Nicolas Lechevalier, Francis Lacombe, et al.
Annales De Biologie Clinique|October 21, 2023
Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patientsVictor-Emmanuel Brett, Marie-Sarah Dilhuydy, Nicolas Lechevalier, et al.
American Journal of Clinical Pathology|November 2, 2018
Reference Values for WBC Differential by Hematoflow AnalysisMarion Magierowicz, Nicolas Lechevalier, Nicolas Freynet, et al.
Ejhaem|February 26, 2024
Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemiaCéline Row, Nicolas Lechevalier, Jean Philippe Vial, et al.
Leukemia Research|January 12, 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry studyIbrahim Didi, Jean-Marc Alliot, Pierre-Yves Dumas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid LeukemiaAlban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Cancer Medicine|February 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapyHarmony Leroy, Noémie Gadaud, Emilie Bérard, et al.
Cancers|July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry StudyPierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Cancers|March 29, 2020
Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry StudySarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, et al.
Pageof 2